Dulaglutide

A once-weekly GLP-1 receptor agonist built as a GLP-1 analog fused to a modified IgG4 Fc domain, approved since 2014 for type 2 diabetes and since 2020 for cardiovascular risk reduction, but never for weight management.

Also referenced as: Trulicity, LY2189265, LY-2189265, GLP-1 Fc fusion protein

Also appears in: Weight loss · Cardiovascular

COA Public product evidence No certificate records are bound to a tracked Dulaglutide product page A record counts here only when a vendor publishes a certificate against one of its own tracked Dulaglutide product pages. Other certificates naming this compound may still exist — search the wider certificate database. →

---

What is Dulaglutide?

Dulaglutide is not a free peptide in the sense most research-market listings imply. It is a recombinant fusion protein of roughly 63 kilodaltons: two identical, disulfide-linked chains, each carrying an N-terminal GLP-1 analog about 90% homologous to native human GLP-1(7-37), joined through a short peptide linker to the Fc region of a modified human IgG4 heavy chain. The GLP-1 portion is altered at the dipeptidyl peptidase-4 cleavage site, and the Fc portion is altered to blunt high-affinity Fc-receptor binding and half-antibody formation. The molecule is expressed in Chinese hamster ovary cell culture, not assembled by solid-phase peptide synthesis.

It was developed by Eli Lilly under the code LY2189265 and approved in the United States as Trulicity on September 18, 2014, becoming one of the first once-weekly GLP-1 receptor agonists. It is of interest to researchers because it is the clearest example of the Fc-fusion route to a long-acting incretin — the alternative to the fatty-acid acylation used in liraglutide and semaglutide — and because it carries a completed, placebo-controlled cardiovascular outcomes trial. It appears in research-peptide catalogs mostly by name, riding on the GLP-1 category rather than on any role in the research market itself.

How it works

• Fc fusion extends the half-life from minutes to days. Native GLP-1 is cleared within minutes by DPP-4 and renal filtration. Fusing a protease-resistant GLP-1 analog to an IgG4 Fc domain produced a molecule that retained full receptor activity in vitro, elicited insulinotropic activity in islets comparable to the native peptide, and showed a half-life of 1.5 to 2 days in rats and cynomolgus monkeys, with immunoreactive active compound persisting beyond six days (Glaesner et al., Diabetes/Metabolism Research and Reviews, 2010;26(4):287–296). In humans the elimination half-life is approximately five days, which is what makes weekly dosing possible.
• Glucose-dependent insulin secretion and glucagon suppression. In a five-week dose-ranging study in 43 adults with type 2 diabetes, once-weekly LY2189265 significantly reduced fasting glucose, two-hour postprandial glucose, and post-meal glucose area under the curve at doses of 1 mg and above, with effects evident after the first dose and sustained across the weekly dosing cycle; most doses raised insulin and C-peptide output when normalized to glucose exposure (Barrington et al., Diabetes, Obesity and Metabolism, 2011;13(5):426–433). The insulinotropic effect is conditional on elevated glucose, the shared property of GLP-1 receptor agonists that keeps intrinsic hypoglycemia risk low.
• Delayed gastric emptying, measurable but modest. In four clinical pharmacology studies in healthy volunteers, a single 1.5 mg dose lowered the peak concentration (significantly for every analyte except R-warfarin) and tended to delay the time to peak of co-administered digoxin, warfarin, atorvastatin, and a combined oral contraceptive, while leaving total exposure essentially unchanged except for a 21% reduction for atorvastatin — the pharmacokinetic signature of slowed gastric emptying without a clinically relevant change in absorption (de la Peña et al., Clinical Pharmacokinetics, 2017;56(11):1415–1427).
• Low immunogenicity despite its size. Across nine Phase 2 and Phase 3 trials with 4,006 dulaglutide-treated patients, treatment-emergent anti-drug antibodies were detected in 1.6%, of whom 0.9% had dulaglutide-neutralizing antibodies and 0.1% had antibodies that neutralized native GLP-1; hypersensitivity events and injection-site reactions were no more frequent than with placebo (Milicevic et al., Diabetes, Obesity and Metabolism, 2016;18(5):533–536). The current label gives the same adult figure (64 of 3,907, 1.6%). The deliberate modifications to a potential T-cell epitope and to the Fc region appear to have done their job.

Research status

Dulaglutide has a deep, sponsor-run Phase 3 record in type 2 diabetes and a positive cardiovascular outcomes trial. Its gaps are in obesity, where it was never tested as a dedicated program, and in head-to-head comparisons against newer incretins, where it loses.

Type 2 diabetes — the AWARD program. The initial 2014 approval rested on the AWARD trials. In AWARD-5, a 104-week adaptive, double-blind trial in 1,098 metformin-treated adults, HbA1c fell 1.10 percentage points with dulaglutide 1.5 mg and 0.87 with 0.75 mg versus 0.39 with sitagliptin 100 mg at 52 weeks, with weight change of −3.03 kg and −2.60 kg versus −1.53 kg (Nauck et al., Diabetes Care, 2014;37(8):2149–2158). AWARD-6, an open-label noninferiority trial in 599 metformin-treated adults, compared weekly dulaglutide 1.5 mg directly with daily liraglutide 1.8 mg: HbA1c reductions were 1.42 versus 1.36 percentage points at 26 weeks (difference −0.06, 95% CI −0.19 to 0.07), with similar nausea, diarrhea, and discontinuation rates (Dungan et al., Lancet, 2014;384(9951):1349–1357). AWARD-11 (NCT03495102) later tested higher doses in 1,842 adults inadequately controlled on metformin: at 36 weeks, 4.5 mg lowered HbA1c by 1.77 percentage points versus 1.54 with 1.5 mg under the treatment-regimen estimand, and body weight by 4.6 versus 3.0 kg; the 3.0 mg dose was superior to 1.5 mg for HbA1c only under the efficacy estimand (Frias et al., Diabetes Care, 2021;44(3):765–773). FDA approved the 3 mg and 4.5 mg strengths on September 3, 2020.

Cardiovascular outcomes — REWIND. REWIND (NCT01394952) randomized 9,901 adults aged 50 or older with type 2 diabetes to weekly dulaglutide 1.5 mg or placebo at 371 sites in 24 countries and followed them for a median 5.4 years — the longest median follow-up of the GLP-1 cardiovascular outcomes trials to date. Unusually, only 31.5% had established cardiovascular disease at baseline and median HbA1c was just 7.2%, making it closer to a primary-prevention population than LEADER or SUSTAIN-6. The primary composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death occurred in 12.0% on dulaglutide versus 13.4% on placebo (hazard ratio 0.88, 95% CI 0.79–0.99; p=0.026). All-cause mortality did not differ significantly (10.8% versus 12.0%; hazard ratio 0.90, 95% CI 0.80–1.01). Gastrointestinal adverse events were reported by 47.4% versus 34.1% (Gerstein et al., Lancet, 2019;394(10193):121–130). The effect was a 12% relative reduction — real, but smaller than the 26% seen with semaglutide in SUSTAIN-6 or the 13% with liraglutide in LEADER, and the trial populations differ enough that cross-trial ranking is unreliable. FDA added the cardiovascular risk-reduction indication on February 21, 2020, and dulaglutide was the first GLP-1 receptor agonist whose cardiovascular label explicitly included adults with multiple risk factors but without established disease.

Pre-specified exploratory analyses of REWIND extended the picture. A composite renal outcome — new macroalbuminuria, a sustained 30% or greater eGFR decline, or chronic renal replacement therapy — occurred in 17.1% versus 19.6% (hazard ratio 0.85, 95% CI 0.77–0.93), driven almost entirely by macroalbuminuria (hazard ratio 0.77); the eGFR-decline component alone was not significant (Gerstein et al., Lancet, 2019;394(10193):131–138). Stroke of any type occurred in 3.2% versus 4.1% (hazard ratio 0.76, 95% CI 0.62–0.94), with the effect concentrated in ischemic stroke (Gerstein et al., Lancet Diabetes & Endocrinology, 2020;8(2):106–114). A cognitive analysis is often over-read: the pre-specified outcome, a substantive decline on the MoCA or Digit Symbol Substitution Test, was not significantly reduced (hazard ratio 0.93, 95% CI 0.85–1.02; p=0.11); the 14% reduction frequently quoted comes from a post-hoc adjustment for baseline scores (Cukierman-Yaffe et al., Lancet Neurology, 2020;19(7):582–590).

Pediatric type 2 diabetes — AWARD-PEDS. In 154 participants aged 10 to under 18 (NCT02963766), 26 weeks of weekly dulaglutide 0.75 mg or 1.5 mg lowered HbA1c by 0.6 and 0.9 percentage points respectively while the placebo group rose by 0.6; 51% of pooled dulaglutide participants versus 14% on placebo reached an HbA1c below 7.0%. There was no between-group difference in BMI change, gastrointestinal adverse events were more frequent than with placebo, and the overall safety profile matched that in adults (Arslanian et al., New England Journal of Medicine, 2022;387(5):433–443). One difference the label records: anti-dulaglutide antibodies appeared in 4% of pediatric patients over the 26-week controlled period and 6% over 52 weeks, against 1.6% in adults. FDA extended the glycemic indication to patients 10 years and older on November 17, 2022.

Where it loses. SUSTAIN 7 randomized 1,201 metformin-treated adults to weekly semaglutide 0.5 mg or 1.0 mg against dulaglutide 0.75 mg or 1.5 mg for 40 weeks. At the higher doses, HbA1c fell 1.8 versus 1.4 percentage points and body weight fell 6.5 versus 3.0 kg (estimated treatment difference −3.55 kg, 95% CI −4.32 to −2.78), with gastrointestinal adverse events in 44% versus 48% (Pratley et al., Lancet Diabetes & Endocrinology, 2018;6(4):275–286). Dulaglutide 1.5 mg was also the active comparator in the Phase 2 trial that introduced tirzepatide: at 26 weeks, HbA1c fell 1.21 percentage points and weight 2.7 kg with dulaglutide, against up to 1.94 points and 11.3 kg at the highest tirzepatide dose (Frias et al., Lancet, 2018;392(10160):2180–2193). In the GLP-1 class dulaglutide now sits as the convenient, well-tolerated weekly option with the smallest weight effect.

As the benchmark in SURPASS-CVOT. The most consequential recent dulaglutide data come from a trial in which it was the comparator rather than the test drug. SURPASS-CVOT (NCT04255433) randomized 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease to weekly tirzepatide (up to 15 mg) or dulaglutide 1.5 mg in a double-blind, active-comparator design. The primary composite of cardiovascular death, myocardial infarction, or stroke occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide (hazard ratio 0.92, 95.3% CI 0.83–1.01); tirzepatide met noninferiority (p=0.003) but not superiority (p=0.09), with more gastrointestinal adverse events (Nicholls et al., New England Journal of Medicine, 2025;393(24):2409–2420). Read in dulaglutide’s favor, a drug with far smaller glycemic and weight effects held its own on hard cardiovascular outcomes against the most potent incretin yet tested — a result that reinforces REWIND’s finding that dulaglutide’s cardiovascular effect is real and not simply a by-product of weight loss.

What was never done. There is no Phase 3 trial of dulaglutide for chronic weight management in people without diabetes, no obesity indication, and no sign of one being pursued; weight loss in the diabetes trials has ranged from about 2 to 5 kg. The 4.5 mg dose is the ceiling tested. Investigator-initiated studies comparing weekly GLP-1 agonists in non-diabetic obesity exist in the registry but are small and not sponsor-run. No Phase 3 program has tested dulaglutide in heart failure, chronic kidney disease as a primary endpoint, NASH, or neurodegenerative disease, so the renal, stroke, and cognitive signals above remain exploratory findings from a single trial.

Common dosage forms

• Single-dose prefilled autoinjector pens at 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg, each in 0.5 mL of solution, the only presentation in the approved US product line. The pen has a hidden needle and fires automatically, which is a notable usability difference from the dial-and-inject pens used for liraglutide and semaglutide.
• The same four pen strengths in the European Union and other markets, where dulaglutide is approved under the same brand; some regions have at times faced supply constraints driven by broader GLP-1 demand.
• No tablet, no multi-dose pen, no vial in any approved product. Dulaglutide has never been formulated for oral delivery, and no biosimilar is approved in the United States.
• Lyophilized “dulaglutide” vials labeled in milligrams appear in some research-market listings. Because the molecule is a glycoprotein-sized Fc fusion that requires mammalian-cell expression, such listings cannot be the product of peptide synthesis, and their relationship to the approved molecule is unverified.

Key considerations

• Approved for diabetes and cardiovascular risk, not for weight. Trulicity holds FDA approval for glycemic control in type 2 diabetes in adults and children aged 10 and older, and for reducing major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors; the FDA Approved status reflects that an FDA-approved drug product containing the molecule exists. Those two indications are the whole of section 1 of the current label (revised March 2026); the earlier “limitations of use” lines about type 1 diabetes and prior pancreatitis no longer appear, and the March 2026 revision itself changed only the warning on severe gastrointestinal adverse reactions. It has no weight-management indication. Any framing of dulaglutide as a weight-loss compound rests on secondary endpoints in diabetes trials, not on an obesity program.
• Boxed warning and labeled safety signals. Like other long-acting GLP-1 receptor agonists, dulaglutide carries a boxed warning for thyroid C-cell tumors based on rodent findings of uncertain human relevance, and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Warnings and precautions cover acute pancreatitis, hypoglycemia when combined with insulin or secretagogues, hypersensitivity, acute kidney injury from volume depletion, severe gastrointestinal reactions (the section revised in March 2026), diabetic retinopathy complications, acute gallbladder disease, and pulmonary aspiration under general anesthesia or deep sedation. REWIND recorded more diabetic retinopathy complications on dulaglutide than placebo (1.9% versus 1.5% overall; 8.5% versus 6.2% in those with prior retinopathy), consistent with the transient worsening seen when glucose control improves rapidly.
• It is not a peptide that can be synthesized, and that matters for research material. A 63-kilodalton disulfide-linked Fc fusion expressed in CHO cells is a biologic, with glycosylation, folding, and aggregation properties that cannot be reproduced by solid-phase chemistry. Material sold as dulaglutide outside the approved product has no approval-derived assurance of identity or activity, and standard peptide purity assays are not designed to characterize it.
• The cardiovascular evidence is good but should be read precisely. REWIND’s 12% relative reduction in MACE was statistically significant with a confidence interval that approaches 1.0, all-cause mortality was not significantly reduced, and the renal, stroke, and cognitive findings were exploratory. Its distinctive strength is the population: a mostly primary-prevention cohort with near-target HbA1c, followed for over five years. SURPASS-CVOT (2025) then showed tirzepatide could not beat dulaglutide on MACE in a 13,000-patient head-to-head, which is as much a statement about dulaglutide’s cardiovascular floor as about tirzepatide’s ceiling.
• Naming and comparison confusions. LY2189265 is the development code; Trulicity is the only brand. Dulaglutide is often grouped with albiglutide, the other long-acting GLP-1 fusion protein — a GLP-1–albumin fusion sold as Tanzeum until its commercial withdrawal in 2018 — and the two should not be confused: different carrier protein, different company, different fate. In head-to-head trials dulaglutide was noninferior to liraglutide for HbA1c (AWARD-6) but inferior to semaglutide for both HbA1c and weight (SUSTAIN 7), so cross-compound claims should name the trial.